Amylyx and Gubra collaborate on GLP-1 antagonist; milestones up to >$50M

Amylyx Pharmaceuticals, Inc.

Collaboration with Gubra to develop a novel long-acting GLP-1 receptor antagonist; Amylyx to make small upfront and research payments (not material).
Gubra eligible for >$50M in success-based development and commercialization milestones plus mid-single digit royalties.
Amylyx expects cash runway into 2026; upfront and research payments not material to the company.
Screening to identify lead development candidate for IND-enabling studies; Amylyx has option to lead development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.